Navigation Links
Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
Date:9/10/2009

WOODCLIFF LAKE, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE :PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for nateglinide tablets. Nateglinide is a generic version of Novartis' Starlix(R). Annual U.S. sales of Starlix(R) are approximately $124 million, according to IMS Health data. Par will begin shipping the 60mg and 120mg strengths of nateglinide to the trade immediately.

Important information about nateglinide tablets

Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes mellitus.

Nateglinide tablets are contraindicated in patients with a known hypersensitivity to the drug or its inactive ingredients, Type I diabetes and diabetic ketoacodosis.

About Par Pharmaceutical

Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds US and European Radiopharmaceuticals Market Report
2. Tianyin Pharmaceutical Co., Inc. Has Four Products Included in Chinas Essential Drug List
3. KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent
4. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
5. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
6. FDA pharmaceutical import alert
7. KV Pharmaceutical Appoints Interim Chief Financial Officer
8. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
9. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia ... Sept. 18 to 20. , The two-day conference is focused on advancing scientific ... of improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent ... is MD Now’s 28th facility overall and marks the urgent care center's eighth location ... mile North of The Falls shopping mall. The new clinic offers a wide array ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
(Date:5/23/2017)... 2017  Leaf Healthcare, recognized for developing one ... pressure ulcer prevention, will unveil its comprehensive mobility ... Care Nurses, National Teaching Institute and Critical Care ... Leaf Patient Monitoring System is the first mobility ... The system seamlessly tracks patient movement throughout the ...
Breaking Medicine Technology: